Xbrane Biopharma AB
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Xbrane Biopharma AB
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. Xbrane’s product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration.
/ 